匹伐他汀钙与阿托伐他汀钙在冠心病临床治疗中的疗效及安全性对比  

Comparison on efficacy and safety of pitavastatin calcium and atorvastatin calcium in the clinical treatment of coronary heart disease

作　　者：李敬品 LI Jing-pin(Shandong Guoxin Nursing Group Zaozhuang Hospital,Zaozhuang 277101,China)

机构地区：[1]山东省国欣颐养集团枣庄医院,277101

出　　处：《中国实用医药》2024年第22期6-10,共5页China Practical Medicine

摘　　要：目的 研究并对比匹伐他汀钙与阿托伐他汀钙在冠心病临床治疗中的疗效及安全性。方法 80例冠心病患者,按随机数字表法分为对照组和研究组,每组40例。对照组应用阿托伐他汀钙治疗,研究组应用匹伐他汀钙治疗。比较两组患者治疗效果、不良反应发生情况、血脂指标(总胆固醇、甘油三酯、低密度脂蛋白胆固醇)、心肌损伤指标(肌钙蛋白I、肌酸激酶同工酶、乳酸脱氢酶)、血液流变学指标(全血高切粘度、全血低切粘度、血浆粘度、红细胞压积)、生活质量评分。结果 研究组治疗总有效率97.50%比对照组的82.50%高(P<0.05)。两组不良反应发生率对比差异不明显(P>0.05)。治疗后,两组患者总胆固醇、甘油三酯、低密度脂蛋白胆固醇比治疗前低,且研究组总胆固醇(4.37±0.74)mmol/L、甘油三酯(1.22±0.33)mmol/L、低密度脂蛋白胆固醇(2.96±0.37)mmol/L均比对照组的(5.24±0.87)、(1.61±0.40)、(3.35±0.39)mmol/L低(P<0.05)。治疗后,两组肌钙蛋白I、肌酸激酶同工酶、乳酸脱氢酶均比治疗前低,且研究组肌钙蛋白I(0.08±0.02)μg/L、肌酸激酶同工酶(16.20±2.39)U/L、乳酸脱氢酶(235.59±10.62)U/L均比对照组的(0.15±0.01)μg/L、(23.39±2.94)U/L、(250.16±12.45)U/L低(P<0.05)。治疗后,两组全血高切粘度、全血低切粘度、血浆粘度、红细胞压积均比治疗前低,且研究组全血高切粘度(4.50±0.43)mPa·s、全血低切粘度(10.75±0.69)mPa·s、血浆粘度(1.68±0.31)mPa·s、红细胞压积(33.27±2.08)%均比对照组的(5.01±0.49)mPa·s、(11.60±0.73)mPa·s、(2.07±0.35)mPa·s、(35.59±2.04)%低(P<0.05)。治疗后,两组生理、心理、环境、社会关系评分均比治疗前高,且研究组生理评分(89.75±6.48)分、心理评分(89.07±6.02)分、环境评分(90.14±6.15)分、社会关系评分(89.96±6.27)分均比对照组的(82.93±6.85)、(82.40±6.13)、(83.27±6.30)、(83.14±6.54)分高(P<0.05)。结论 在冠心病患�Objective To study and compare the efficacy and safety of pitavastatin calcium and atorvastatin calcium in the clinical treatment of coronary heart disease.Methods 80 patients with coronary heart disease were divided into a control group and a study group according to random numerical table,with 40 patients in each group.The control group was treated with atorvastatin calcium,while the study group was treated with pitavastatin calcium.Comparison was made on the treatment effect,occurrence of adverse reactions,blood lipid indicators(total cholesterol,triglyceride,low-density lipoprotein cholesterol),myocardial injury indicators(troponin I,creatine kinase isoenzyme,lactate dehydrogenase),hemorheological indicators(whole-blood high-shear viscosity,whole-blood low-shear viscosity,plasma viscosity,hematocrit),and quality of life scores between and within the two groups.Results The total effective rate of 97.50% in the study group was higher than 82.50% in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).After treatment,the total cholesterol,triglyceride and low-density lipoprotein cholesterol in both groups were lower than those before treatment;in the study group,the total cholesterol was(4.37±0.74) mmol/L,the triglyceride was(1.22±0.33) mmol/L,the low-density lipoprotein cholesterol was(2.96±0.37) mmol/L,which were lower than(5.24±0.87),(1.61±0.40) and(3.35±0.39) mmol/L in the control group(P<0.05).After treatment,the troponin I,creatine kinase isoenzyme and lactate dehydrogenase in both groups were lower than those before treatment;in the study group,the troponin I was(0.08±0.02) μg/L,the creatine kinase isoenzyme was(16.20±2.39) U/L,and the lactate dehydrogenase was(235.59±10.62) U/L,which were lower than(0.15±0.01) μg/L,(23.39±2.94) U/L,and(250.16±12.45) U/L in the control group(P<0.05).After treatment,the whole-blood high-shear viscosity,whole-blood low-shear viscosity,plasma viscosity,and hematocrit in both groups we

关 键 词：冠心病 阿托伐他汀钙 匹伐他汀钙 血脂 心肌损伤 疗效 安全性 

分 类 号：R541.4[医药卫生—心血管疾病]